CARDIAMIN (multivitamin with min/folic acid/d3/omega-3/dha/epa/fish oil)


Drug overview for CARDIAMIN (multivitamin with min/folic acid/d3/omega-3/dha/epa/fish oil):

Generic name: MULTIVITAMIN WITH MIN/FOLIC ACID/D3/OMEGA-3/DHA/EPA/FISH OIL
Drug class: Multivitamins
Therapeutic class: Electrolyte Balance-Nutritional Products

Folic acid is a water-soluble, B complex vitamin.

Numerous multivitamin preparations are marketed, with little Vitamin D analogs are used to prevent or treat rickets or osteomalacia and standardization of formulas. Useful multivitamin preparations should to manage hypocalcemia associated with hypoparathyroidism or contain only essential vitamins (those for which there is a recommended pseudohypoparathyroidism. Since calcitriol is more expensive than daily dietary allowance (RDA)). (See Dosage and Administration.) ergocalciferol, use of the former drug is generally reserved for patients Preparations containing iron and/or calcium supplements may be useful in with inadequate metabolism of ergocalciferol.

The initial treatment of severe hypocalcemia is immediate IV administration of a calcium salt such some patients (e.g., pregnant or lactating women) but other essential as calcium gluconate. Vitamin D analogs are then used to maintain minerals are usually obtained from the diet. The addition of agents such as liver, yeast, and wheat germ to vitamin preparations offers no advantage normocalcemia.

Because of its shorter onset of action, calcitriol may be over pure chemical ingredients, and inclusion of nonessential agents such preferable to ergocalciferol in the acute treatment of hypocalcemia. as choline, bioflavonoids, inositol, betaine, lecithin, and methionine is Oral calcitriol also is used in the management of secondary unwarranted. Combinations of vitamins and other drugs such as hormones are hyperparathyroidism and resultant metabolic bone disease in patients with irrational and should not be used.

moderate to severe chronic kidney disease (CKD) who do not yet require maintenance dialysis therapy (predialysis patients) and in the management of hypocalcemia and resultant metabolic bone disease in patients with CKD undergoing dialysis. IV calcitriol is used in the management of hypocalcemia in patients with chronic renal failure undergoing dialysis. IV or oral doxercalciferol is used for the treatment of secondary hyperparathyroidism in patients with CKD undergoing dialysis.

Oral doxercalciferol also is used for the treatment of secondary hyperparathyroidism in patients with stage 3 or 4 CKD who do not yet require maintenance dialysis (predialysis patients). IV paricalcitol is used in the prevention and treatment of secondary hyperparathyroidism in patients with stage 5 CKD, while oral paricalcitol is used in the prevention and treatment of secondary hyperparathyroidism in patients with stage 3 or 4 CKD as well as in those with stage 5 CKD requiring hemodialysis or peritoneal dialysis. Calcifediol is used in the treatment of secondary hyperparathyroidism in patients with stage 3 or 4 CKD and vitamin D insufficiency.

Because of the risk of toxicity, therapy with vitamin D analogs should be closely monitored, and indiscriminate use of these drugs should be avoided. Folic acid is used for the treatment of megaloblastic and macrocytic anemias resulting from folate deficiency. The drug is usually indicated in the treatment of nutritional macrocytic anemia; megaloblastic anemias of pregnancy, infancy, and childhood; and megaloblastic anemia associated with primary liver disease, alcoholism and alcoholic cirrhosis, intestinal strictures, anastomoses, or sprue.

Folate deficiency may also result from increased loss of folate secondary to renal dialysis or the administration of some drugs such as phenytoin, primidone, barbiturates, methotrexate, nitrofurantoin, or sulfasalazine. Folic acid is not effective in the treatment of normocytic, refractory, or aplastic anemias or, when used alone, in the treatment of pernicious anemia. Folic acid antagonists (e.g., methotrexate, pyrimethamine, trimethoprim) inhibit folic acid reductases and prevent the formation of tetrahydrofolic acid.

Therefore, folic acid is not effective as an antidote following overdosage of these drugs, and leucovorin calcium must be used. In large doses, folic acid is used in the treatment of tropical sprue. In patients with this disease, the drug appears to exert a beneficial effect on the underlying mucosal abnormality as well as to correct folate deficiency.

Although prophylactic administration of folic acid is not required in most individuals, supplemental folic acid may be required to prevent deficiency of the vitamin in patients with conditions that increase folic acid requirements such as pregnancy, nursing, or chronic hemolytic anemia. In some patients, such as those with nutritional megaloblastic anemia associated with vitamin B12 deficiency or tropical or nontropical sprue, a simultaneous deficiency of folic acid and cyanocobalamin may exist, and combined therapy may be warranted. Likewise, combined folic acid and iron therapy may be indicated for prevention or treatment of megaloblastic anemia associated with iron deficiency as may occur in conditions such as sprue, megaloblastic anemia of pregnancy, and megaloblastic anemia of infants.
DRUG IMAGES
  • No Image Available
    No Image Available
The following indications for CARDIAMIN (multivitamin with min/folic acid/d3/omega-3/dha/epa/fish oil) have been approved by the FDA:

Indications:
Mineral deficiency prevention
Mineral deficiency
Vitamin deficiency prevention
Vitamin deficiency


Professional Synonyms:
Vitamin deficiency prophylaxis